ReviewMolecules (Basel, Switzerland)2020
The Renal Clearable Magnetic Resonance Imaging Contrast Agents: State of the Art and Recent Advances.
Review in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 26 citations in OpenAlex.
- Safety, In Vivo Fate, and Degradation of MOF Nanomedicines: Toward Translational Evaluation.Pharmaceutics · 2026Review
- Physicochemical and Multimodal Imaging Properties of Core-Shell LnMolecules (Basel, Switzerland) · 2025Article
- Current Status and Future Aspects of Gadolinium Oxide Nanoparticles as Positive Magnetic Resonance Imaging Contrast Agents.Nanomaterials (Basel, Switzerland) · 2025Review
- Enhanced detection of glioblastoma vasculature with superparamagnetic iron oxide nanoparticles and MRI.Scientific reports · 2025Article
- PD-L1 blockade peptide-functionalized NaGdFRSC advances · 2025Article
- The role of manganese-based MRI contrast agents for cancer theranostics: Where do we stand in 2025?Theranostics · 2025Review
- Application of HInternational journal of molecular sciences · 2024Article
- Employing antagonistic C-X-C motif chemokine receptor 4 antagonistic peptide functionalized NaGdFScientific reports · 2024Article
- Feasibility and safety of contrast-enhanced magnetic resonance-guided adaptive radiotherapy for upper abdominal tumors: A preliminary exploration.Physics and imaging in radiation oncology · 2024Article
- Genetically encoded discovery of perfluoroaryl macrocycles that bind to albumin and exhibit extended circulation in vivo.Nature communications · 2023Article
- Current practices and perspectives on the integration of contrast agents in MRI-guided radiation therapy clinical practice: A worldwide survey.Clinical and translational radiation oncology · 2023Article
- Carboxylated superparamagnetic FeBMC cancer · 2023Article
- Unleashing novel horizons in advanced prostate cancer treatment: investigating the potential of prostate specific membrane antigen-targeted nanomedicine-based combination therapy.Frontiers in immunology · 2023Review
- A Comprehensive Updated Review on Magnetic Nanoparticles in Diagnostics.Nanomaterials (Basel, Switzerland) · 2021Review
- The Peptide Functionalized Inorganic Nanoparticles for Cancer-Related Bioanalytical and Biomedical Applications.Molecules (Basel, Switzerland) · 2021Review
- Synthesis of Bis(Carboranyl)amides 1,1'-μ-(CHMolecules (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
The advancements of magnetic resonance imaging contrast agents (MRCAs) are continuously driven by the critical needs for early detection and diagnosis of diseases, especially for cancer, because MRCAs improve diagnostic accuracy significantly. Although hydrophilic gadolinium (III) (Gd
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.